IMPLEMENTING COVID-19 TESTING AT OUR SCHOOL

Keeping our school safe is job #1 and that's why we've partnered with BD, an industry leader in rapid antigen testing, to provide onsite COVID-19 diagnostic testing in our school. This is a rapid antigen test that will be administered by trained school staff and was chosen because of the many advantages offered by the **BD Veritor™ Plus System**.

Comfortable nasal swab – Unlike tests that you may have had or seen in the past, this test utilizes a much less invasive nasal swab for sample collection. So the process is simple and painless.

Results in 15 minutes – Tests are performed on a analyzer at our school and results are produced in about 15 minutes. So we have the ability to respond quickly.

Proven, digitally read results – The analyzer produces digitally read results that eliminate ambiguity and deliver clear and confident results.

We believe that proactively implementing this onsite approach to testing will help us all begin to get back to normal with a greater sense of confidence. Should you have any questions about our COVID-19 testing program, please feel free to contact:

Should you have questions about your COVID-19 testing program, please contact **1-888-4BDCOVID** and **veritorcares@bd.com**

*Information about the BD Veritor™ System for Rapid Detection of SARS-CoV-2:

- This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories
- This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and
- This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The BD Veritor™ System for Rapid Detection of SARS-CoV-2 is a chromatographic digital immunoassay intended for the direct and qualitative detection of SARS-CoV-2 nucleocapsid antigens in nasal swabs from individuals who are suspected of COVID-19 by their healthcare provider within the first five days of the onset of symptoms. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

BDVeritor.com

BD